BACKGROUND: The high incidence of @entity263 as the most common @entity5 in males in many countries raises the question of developing reliable detection tests. The @entity1486 ( @entity1486 ) test is the most widely used for screening for @entity263 ; however, its low specificity elevates the number of unnecessarily biopsies. Serum human kallikrein-2 ( @entity14958 ) is considered as a promising marker, and especially its ratio to fPSA, for predicting the presence of @entity5 to select the best choice referring to biopsy or surveillance. In this study, we investigated the role of @entity14958 and its combinations with other markers to discriminate @entity263 from benign diseases in Syrian @entity1 . MATERIALS AND METHODS: In this prospective oriented cross-sectional cohort study, serum samples were collected from @entity1 referred to many Hospitals in Damascus, Syria, between May 2011 and March 2012, and diagnosed with biopsy proven @entity263 ( @entity263 ). Serum was analyzed for @entity14958 , @entity1486 and fPSA, and the ratios of @entity1486 and @entity14958 /fPSA were calculated. RESULTS: We found that mean @entity14958 /fPSA ratios were significantly higher (P=0.01) in @entity263 @entity1 than in the @entity1067 or control groups. Also the ratio @entity26256 /fPSA gave the largest area under the curve (AUC:0.96) which was significantly larger than for @entity1486 (AUC:0.41) indicative of higher specificity. CONCLUSIONS: Our results demonstrate that the ratio of @entity14958 /fPSA might be superior to the use of @entity1486 alone. The @entity14958 could be shown to enhance the early detection of @entity263 ; especially the ratio @entity14958 /fPSA improves specificity and hence may reduce the number of negative biopsies.

@entity1 Kallikrein-2, @entity1486 and Free- @entity1486 in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity14958 :: ('58164', 'Gene') :: ['hK2'] @entity263 :: ('MESH:D011471', 'Disease') :: ['benign prostate hyperplasia (BPH) or prostate cancer', 'prostate cancer', 'PCa'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity1067 :: ('MESH:D011470', 'Disease') :: ['BPH'] @entity26256 :: ('3099', 'Gene') :: ['hk2'] @entity1486 :: ('354', 'Gene') :: ['fPSA/PSA', 'PSA', 'prostate specific antigen']
@entity1 :: (9606,Species) :: ['Patients']
